These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 22733600)

  • 1. Compatibility, physical stability, and characterization of an IgG4 monoclonal antibody after dilution into different intravenous administration bags.
    Kumru OS; Liu J; Ji JA; Cheng W; Wang YJ; Wang T; Joshi SB; Middaugh CR; Volkin DB
    J Pharm Sci; 2012 Oct; 101(10):3636-50. PubMed ID: 22733600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a microflow digital imaging assay to characterize protein particulates during storage of a high concentration IgG1 monoclonal antibody formulation.
    Wuchner K; Büchler J; Spycher R; Dalmonte P; Volkin DB
    J Pharm Sci; 2010 Aug; 99(8):3343-61. PubMed ID: 20229596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Label-free flow cytometry analysis of subvisible aggregates in liquid IgG1 antibody formulations.
    Nishi H; Mathäs R; Fürst R; Winter G
    J Pharm Sci; 2014 Jan; 103(1):90-9. PubMed ID: 24218205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Equilibrium studies of protein aggregates and homogeneous nucleation in protein formulation.
    Kiese S; Pappenberger A; Friess W; Mahler HC
    J Pharm Sci; 2010 Feb; 99(2):632-44. PubMed ID: 19548315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of the physical stability of a lyophilized IgG1 mAb after accelerated shipping-like stress.
    Telikepalli S; Kumru OS; Kim JH; Joshi SB; O'Berry KB; Blake-Haskins AW; Perkins MD; Middaugh CR; Volkin DB
    J Pharm Sci; 2015 Feb; 104(2):495-507. PubMed ID: 25522000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of a dual-wavelength size exclusion HPLC method with improved sensitivity to detect protein aggregates and its use to better characterize degradation pathways of an IgG1 monoclonal antibody.
    Bond MD; Panek ME; Zhang Z; Wang D; Mehndiratta P; Zhao H; Gunton K; Ni A; Nedved ML; Burman S; Volkin DB
    J Pharm Sci; 2010 Jun; 99(6):2582-97. PubMed ID: 20039394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural characterization of IgG1 mAb aggregates and particles generated under various stress conditions.
    Telikepalli SN; Kumru OS; Kalonia C; Esfandiary R; Joshi SB; Middaugh CR; Volkin DB
    J Pharm Sci; 2014 Mar; 103(3):796-809. PubMed ID: 24452866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of subvisible particle formation during the filling pump operation of a monoclonal antibody solution.
    Nayak A; Colandene J; Bradford V; Perkins M
    J Pharm Sci; 2011 Oct; 100(10):4198-204. PubMed ID: 21698601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of Nanoparticle Tracking Analysis for Quantification and Sizing of Submicron Particles of Therapeutic Proteins.
    Zhou C; Krueger AB; Barnard JG; Qi W; Carpenter JF
    J Pharm Sci; 2015 Aug; 104(8):2441-50. PubMed ID: 26017684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stability of lyophilized sucrose formulations of an IgG1: subvisible particle formation.
    Davis JM; Zhang N; Payne RW; Murphy BM; Abdul-Fattah AM; Matsuura JE; Herman AC; Manning MC
    Pharm Dev Technol; 2013; 18(4):883-96. PubMed ID: 22813478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Free fatty acid particles in protein formulations, part 2: contribution of polysorbate raw material.
    Siska CC; Pierini CJ; Lau HR; Latypov RF; Fesinmeyer RM; Litowski JR
    J Pharm Sci; 2015 Feb; 104(2):447-56. PubMed ID: 25196966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Comprehensive Evaluation of Nanoparticle Tracking Analysis (NanoSight) for Characterization of Proteinaceous Submicron Particles.
    Tian X; Nejadnik MR; Baunsgaard D; Henriksen A; Rischel C; Jiskoot W
    J Pharm Sci; 2016 Nov; 105(11):3366-3375. PubMed ID: 27663383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microparticles and Nanoparticles Delivered in Intravenous Saline and in an Intravenous Solution of a Therapeutic Antibody Product.
    Pardeshi NN; Qi W; Dahl K; Caplan L; Carpenter JF
    J Pharm Sci; 2017 Feb; 106(2):511-520. PubMed ID: 27832839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the Role of the Air-Solution Interface on the Mechanism of Subvisible Particle Formation Caused by Mechanical Agitation for an IgG1 mAb.
    Ghazvini S; Kalonia C; Volkin DB; Dhar P
    J Pharm Sci; 2016 May; 105(5):1643-1656. PubMed ID: 27025981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stability of IgG1 monoclonal antibodies in intravenous infusion bags under clinical in-use conditions.
    Sreedhara A; Glover ZK; Piros N; Xiao N; Patel A; Kabakoff B
    J Pharm Sci; 2012 Jan; 101(1):21-30. PubMed ID: 21905032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physical characterization and in vitro biological impact of highly aggregated antibodies separated into size-enriched populations by fluorescence-activated cell sorting.
    Telikepalli S; Shinogle HE; Thapa PS; Kim JH; Deshpande M; Jawa V; Middaugh CR; Narhi LO; Joubert MK; Volkin DB
    J Pharm Sci; 2015 May; 104(5):1575-91. PubMed ID: 25753756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compatibility and stability of pertuzumab and trastuzumab admixtures in i.v. infusion bags for coadministration.
    Glover ZW; Gennaro L; Yadav S; Demeule B; Wong PY; Sreedhara A
    J Pharm Sci; 2013 Mar; 102(3):794-812. PubMed ID: 23225178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subvisible particle counting provides a sensitive method of detecting and quantifying aggregation of monoclonal antibody caused by freeze-thawing: insights into the roles of particles in the protein aggregation pathway.
    Barnard JG; Singh S; Randolph TW; Carpenter JF
    J Pharm Sci; 2011 Feb; 100(2):492-503. PubMed ID: 20803602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterisation of Stress-Induced Aggregate Size Distributions and Morphological Changes of a Bi-Specific Antibody Using Orthogonal Techniques.
    Hamrang Z; Hussain M; Tingey K; Tracka M; Casas-Finet JR; Uddin S; van der Walle CF; Pluen A
    J Pharm Sci; 2015 Aug; 104(8):2473-81. PubMed ID: 26053418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Approach to Mitigate Particle Formation on the Dilution of a Monoclonal Antibody Drug Product in an IV Administration Fluid.
    Zheng S; Adams M; Mantri RV
    J Pharm Sci; 2016 Mar; 105(3):1349-50. PubMed ID: 26886343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.